Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 318

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 19
Chunk 318
---
4, relating to the "AGA Perf Employees 2021-1" and "AGA Perf Management 2021-1" free performances shares plans, granted on October 1, 2021. The definitive performance was 80 51,404 612,080

F-19

acquisition of 416,000 1,028,080 0.05

2)Accounting policies and statement of compliance

a)Basis of preparation

Consolidated financial statements of the Company for the years ended December 31, 2022, 2023 and 2024 (the “ Consolidated Financial Statements”) have been prepared under the responsibility of the management of the Company in accordance with the underlying assumptions of going concern as the Company’s loss-making situation is explained by the innovative nature of the products developed, therefore involving a multi-year research and development Phase.

The general accounting conventions were applied in compliance with the principle of prudence, in accordance with the underlying assumptions namely (i) going concern, (ii) permanence of accounting methods from one year to the next and (iii) independence of financial years, and in conformity with the general rules for the preparation and presentation of consolidated financial statements in accordance with IFRS, as defined below.

Except for share data and per share amounts, the Consolidated Financial Statements are presented in thousands of euro. Amounts are rounded up or down to the nearest whole number for the calculation of certain financial data and other information contained in these accounts. Accordingly, the total amounts presented in certain tables may not be the exact sum of the preceding figures

b)Statement of compliance

The Consolidated Financial Statements have been prepared in accordance with IFRS Accounting Standards (“IFRS”) as issued by the International Accounting Standard Board (“ IASB”) and were approved and authorized for issuance by the Board of Directors of the Company on April 24, 2025. They will be approved by the General Meeting of the Company on May 22, 2025, which has the right to modify them.

Due to the listing of ordinary shares of the Company on Euronext Paris and in accordance with the European Union’s regulation No. 1606/2002 of July 19, 2002, the Consolidated Financial Statements of the Company for the years ended December 31, 2022, 2023 and 2024 are also prepared in accordance with IFRS, as adopted by the European Union (EU). For the years ended December 31